| Type | Subsidiary |
| HQ | Valbonne, FR |
| Founded | 2001 |
| Website | txcell.com |
| Cybersecurity rating | BMore |
TxCell was founded in 2001 and is headquartered in Valbonne, FR
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at TxCell
Stephane Boissel
CEO
Raphael Flipo
SVP, Chief Financial Officer
Francois Meyer
Chairman of the Board and Head of Research
TxCell Office Locations
TxCell has an office in Valbonne
Valbonne, FR (HQ)
Allée de la Nertière
TxCell Financials and Metrics
Summary Metrics
Founding Date | 2001 |
Total Funding | $71.6 m |
Investors | Bpifrance, Seventure Partners, Ardian, Auriga Partners, Innovation Capital, Bioam Gestion, InnoBio Fund |
TxCell Revenue
TxCell's revenue was reported to be €2.23 m in FY, 2017 which is a 24.2% decrease from the previous period.
Annual
Annual
| EUR | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|
Net Income | (8.3m) | (11.3m) | (13.6m) | (10.9m) |
Depreciation and Amortization | 460.0k | 1.1m | (326.0k) | 272.0k |
Accounts Payable | 5.8m | 213.0k | (714.0k) | (19.0k) |
Cash From Operating Activities | (6.9m) | (10.1m) | (10.4m) | (9.8m) |
Half Year
| EUR | H1, 2015 | H1, 2016 | H1, 2017 |
|---|---|---|---|
Net Income | (5.7m) | (7.1m) | (5.3m) |
Depreciation and Amortization | 257.0k | (445.0k) | 107.0k |
Accounts Payable | (146.0k) | 503.0k | 219.0k |
Cash From Operating Activities | (6.3m) | (6.1m) | (5.1m) |
| EUR | FY, 2014 |
|---|---|
Debt/Equity | 0.1 x |
Debt/Assets | 0.1 x |
Financial Leverage | 1.4 x |
TxCell Cybersecurity Score
TxCell Online and Social Media Presence
460 Twitter followers
TxCell has 460 Twitter Followers. The number of followers has increased 1.8% month over month and increased 6.9% quarter over quarter
TxCell's Trends
Twitter Engagement Stats for @TxCellSA
352
Tweets
67
Following
460
Followers
2
Tweets last 30 days
0.5
Avg. likes per Tweet
50%
Tweets with engagement
TxCell News and Updates
July 23, 2018
Sangamo Therapeutics to Acquire TxCell
RICHMOND, Calif. and VALBONNE, France, July 23, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) and TxCell S.A. (ENXTPA: TXCL) announced today that they have entered into a definitive agreement on July 20, 2018 pursuant to which Sangamo will, following the completion of the ...
TxCell Blogs
May 24, 2021
Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer
BRISBANE, Calif. --(BUSINESS WIRE)--May 24, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial Officer, effective June 1, 2021 . Ms.
May 21, 2021
Sangamo Therapeutics Announces Participation at Jefferies Healthcare Conference
BRISBANE, Calif. --(BUSINESS WIRE)--May 21, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 4 th at 11am Eastern Time .
May 04, 2021
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time BRISBANE, Calif. --(BUSINESS WIRE)--May 4, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and first quarter 2021 financial results.
April 27, 2021
Sangamo Therapeutics Announces Presentations at 2021 Annual Meeting of the American Society of Gene & Cell Therapy
BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 27, 2021-- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced upcoming data presentations at the 24 th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held May 11-14, 2021 , in a virtual form…
April 27, 2021
Sangamo Therapeutics Announces First Quarter 2021 Conference Call and Webcast
BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 27, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its first quarter 2021 financial results after the market closes on Tuesday, May 4, 2021 .
March 25, 2021
Sangamo Therapeutics Announces Participation at Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease
Sangamo Therapeutics Announces Participation at Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease
Content Import
Thu, 03/25/2021 - 08:31
Sangamo Therapeutics Announces Participation at Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease
…
TxCell Frequently Asked Questions
When was TxCell founded?
TxCell was founded in 2001.
Who are TxCell key executives?
TxCell's key executives are Stephane Boissel, Raphael Flipo and Francois Meyer.
How many employees does TxCell have?
TxCell has 17 employees.
What is TxCell revenue?
Latest TxCell annual revenue is €2.2 m.
What is TxCell revenue per employee?
Latest TxCell revenue per employee is €131.4 k.
Who are TxCell competitors?
Competitors of TxCell include Bioz, Karius and eGenesis.
Where is TxCell headquarters?
TxCell headquarters is located at Allée de la Nertière, Valbonne.
Where are TxCell offices?
TxCell has an office in Valbonne.
How many offices does TxCell have?
TxCell has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies